Icon

NORVASC (nda019787)- (EQ 2.5MG BASE,EQ 5MG BASE,EQ 10MG BASE)

AMLODIPINE BESYLATE VIATRIS
EQ 2.5MG BASE,EQ 5MG BASE,EQ 10MG BASE
Yes No
2007-Sep-25 Expired
None None
None No
NORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension o NORVASC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease o Chronic Stable Angina o Vasospastic Angina (Prinzmetal’s or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%.
20 0 13
Total Other Developers 15
Drugs with Suitability No
EQ 2.5MG BASE ** ** - - 11
EQ 5MG BASE ** ** Up 10 -
EQ 10MG BASE ** ** Up 10 -
NDA Sales Available Total Generic Sales Available
Yes 10
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** **** ************** ********** ***. *********** ** *** ******* ******, ********** ****, **** ****, *******, ****** (***) ***
****** ***** ***** ******* *** *********** **********, *** ****** ****, *********, ********* ******, ***** (***) ***
****** ***** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ***** ***** ******* *********** **** **. * &** ****** ******* ******** ****, ***** **, ********* ****, ****** ******* ******, ***** (***) ***
****** ***** ***** ******* *********** **** **. *-*, *-**, *-** *** *-**/*/*, ********** ********** ****, ******, *********** ******, ***** (***) ***
****** ******* ****** ******* ******* ******* ******* *********** **** **. ***, ***, ***, *** & ***, ***** ************** *******, *******, ************, ***** **** ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ***** ****** *** ***** ************ ******* *********** ******* ****** *****, *.*. *****, ******-********, *****, ******** ******* ******, ***** (***) ***
****** ***** ****** *** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ****** ****** ****** ***************, *** *********** *** **** **** *******, **********, ******* (**) *****, ****** ****** (***) ***
****** ***** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***
****** ***** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***
****** ***** *** ****** ******* ******* *********** ****** **. ** ** **, ******* *******, **********, ****** ******* ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ******* ****** ******* *************** ***. *********** ** ******** ***, **** **, ********, *** **** (**) *****, ****** ****** (***) ***
****** ***** ***** ******* *********** * **-*, **** ********** ****, ***********, **********, *********** ******, ***** (***) ***
****** ***** ***** ******* *********** **** *-*, *-**, *-** **** ********** ****, ******** *******, ******-*****, ****, *********** ******, ***** (***) ***
****** ******* ******* ************ ******* *********** **** **. ** ** **, ******* ********** ******, *******, ******, *** ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ******* ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.